Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AURKB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | AURKB Recombinant Protein / Mutant Kinase High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View AURKB Products |
| Gene Delivery | AURKB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View AURKB Products |
| Benchmark Ab | Anti-AURKB Benchmark Antibody / Recombinant Antibody (Rabbit mAb) Positive control for western blot, IF, ELISA. |
View AURKB Products |
| Validator | AURKB siRNA Set For knockdown verification. |
View AURKB Products |
| Related Target A | AURKA (Aurora Kinase A) High-homology off-target; essential for selectivity profiling. |
View AURKA Products |
| Related Target B | INCENP Chromosomal passenger complex (CPC) partner essential for native AURKB kinase activation. |
View INCENP Products |
| Related Target C | BIRC5 (Survivin) CPC partner; synergistic oncology target for combination studies. |
View BIRC5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity (AURKA/AURKC off-target) | AURKB, AURKA, and AURKC recombinant kinase proteins available in parallel; Sequence Verified; High Purity (>95%) for side-by-side IC50 profiling. |
| Cell-Based Target Engagement | AURKB Lentivirus Premade Particles for stable cell line generation; preserves native folding and cellular context. |
| Assay Specificity & False Positives | Matched anti-AURKB recombinant antibody and siRNA set included for orthogonal validation. |
| Resistance Mutation Screening | Custom AURKB Mutant Recombinant Proteins (predicted drug-resistant variants) available; Sequence Verified. Also includes known mutations like rs55878091, rs3027254, rs55871613. |
| Enzymatic Assay Standardization | High Purity (>95%) kinases, Theoretical MW confirmed, rationally designed for HTS. |
| Lack of Reliable Controls | Recombinant positive control antibodies included. |
Live AURKB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AURKB therapeutics has evolved from first-generation pan-Aurora inhibitors toward highly selective small molecules and targeted protein degradation strategies. Early clinical programs (e.g., AstraZeneca's AZD1152/Barasertib, Takeda's TAK-901, Pfizer's PF-03814735) highlighted significant hematologic toxicity (myelosuppression) and limited therapeutic windows, driving the industry to demand stringent selectivity over AURKA and AURKC. As next-generation covalent inhibitors and PROTACs enter preclinical development, the emphasis has shifted to combination regimens—pairing AURKB blockade with CDK1, PLK1, or BCL-2 pathway inhibitors—to improve efficacy while mitigating toxicity. The future landscape will be defined by the ability to engineer molecules with exquisite kinase-domain selectivity and rational resistance-bypass profiles, including PROTAC-mediated degradation that circumvents traditional ATP-binding site mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | AstraZeneca, Chia Tai Tianqing; Legacy programs (AZD1152, TAK-901, PF-03814735) | Leukemia, Solid Tumors | Selectivity Assay (Need AURKB vs AURKA/AURKC WT proteins) |
| PROTAC / Degrader | Preclinical Biotech Innovators; Emerging biotech/academic consortia | Refractory Cancers, Solid Tumors | Degradation Assays (Need Lentivirus for Cell Line creation) |
| Combination Therapy | Various | NSCLC, Breast Cancer | Synergy Validation (Need siRNA for mechanistic decoupling) |
| RNAi / siRNA | Platform developers | Hematologic Malignancies | Knockdown Verification (Need validated AURKB siRNA) |